Sucampo plans mid-year US filing for lubiprostone in opioid-induced bowel dysfunction
This article was originally published in Scrip
Executive Summary
Sucampo Pharmaceuticals says the company now has the long-term data it needs to support a supplemental new drug application (sNDA) to the US FDA for its drug lubiprostone to treat opioid-induced bowel dysfunction (OBD) in patients with chronic non-cancer-related pain.